Pharmaceutical products and services company Thermo Fisher Scientific (NYSE: TMO)’s acquisition of CorEvitas from Audax Private Equity complements its clinical research business. The deal was a $912.5 million all-cash transaction.
To read the entire story, you must be logged in.
Please log in now or register with us.
